Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
3/17/2025
BeiGene and Amgen Launch Phase 1 Trial of Tarlatamab + YL201 in China
3/17/2025
SinoCellTech Advances PD-1/VEGF Bispecific SCTB14 into Phase 2/3 for E...
3/17/2025
China Suspends Imports of Five APIs from Kyowa Hakko Bio's Hofu Plant
3/17/2025
NMPA Solicits Comments on Draft Revision of GMP Annex for Sterile Drug...
3/17/2025
Visirna Announce Positive Topline Results from Phase 3 Trial of Ploza...
3/17/2025
Innovent Launches GLORY-3: A Phase 3 Head-to-Head Study of Mazdutide v...
3/14/2025
Roche's Itovebi (Inavolisib) Wins Approval in China for Advanced Breas...
3/14/2025
BioCity Announces Clinical Collaboration to Evaluate BC3195 in Combo w...
3/14/2025
Pyrotech's PTT-936 Gains Approval for Clinical Trials in China for Adv...
3/14/2025
Fosun Pharma to Divest United Family Healthcare for $124.1M
3/14/2025
Zai Lab/Pfizer's BLA for Tivdak Accepted in China
3/14/2025
Innovent's IBI311 Becomes First Chinese-Made IGF-1R Antibody Approved ...
3/14/2025
Recent Executive Moves
3/14/2025
PharmCube's Overview and Insights into China's Pharmaceutical Market 2...
3/13/2025
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation...
3/13/2025
China Issues Guidelines for Informatization of County-Level Healthcare...
3/13/2025
Insilico Medicine Secures $110M, Explores IPO Amid AI Drug Discovery B...
3/12/2025
Akeso Initiates Phase III Trial of Ivonescimab Plus Chemotherapy for m...
3/12/2025
CSPC Advances Phase II Trial of Nectin-4 ADC SYS6002 for Advanced HNSC...
3/12/2025
Eli Lilly Plans Late 2025 Launch of Weight Loss Drugs in China and Ind...
3/12/2025
Pfizer's PD-L1 Targeting ADC Receives Clinical Trial Approval in China
3/12/2025
CDE Publicizes the List of Reference Formulations for GQCE Studies (91...
3/12/2025
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generati...
3/12/2025
Novartis' Cosentyx Receives Fifth Indication Approval in China for Hid...
3/12/2025
NewDEL Biotech Completes Series A+ Financing Led by XtalPi to Accelera...
3/11/2025
TYK Medicines Announces Pivotal Phase II Trial of TY-9591 Vs Osimertin...
3/11/2025
InnoCare Presents Promising Phase II Data on ICP-488 for Psoriasis
3/11/2025
RockRoc Secures Pre-A+ Financing to Advance Macrophage-Based Cancer Th...
3/11/2025
Juvensis Secures Over CNY 100M in Pre-A Financing to Advance Gene The...
3/11/2025
Pfizer's Elrexfio Receives Conditional Approval in China for Advanced ...
Page:
9
/
764
Total number of articles:
22895
:
[First]
[<<]
[7]
[8]
[9]
[10]
[11]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit